Business Context and Reporting Period
This Form 8-K is filed by pSivida Corp. (not Eyepoint, Inc.) on October 17, 2013, reporting events occurring on October 18, 2013. The registrant is a Delaware corporation headquartered in Watertown, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than financial performance.
Material Changes
The primary material event is the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for ILUVIEN® for diabetic macular edema. The CRL indicates the NDA could not be approved in its present form. This application was submitted by pSivida's licensee, Alimera Sciences, Inc.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future outlook. The receipt of the CRL represents a significant regulatory risk and contingency, as it delays or prevents the commercialization of ILUVIEN® for the indicated condition until the FDA's concerns are addressed.
Investor Verification Checklist
- Verify the specific deficiencies cited in the FDA's Complete Response Letter for ILUVIEN®.
- Confirm the timeline and strategy Alimera Sciences, Inc. plans to address the FDA's concerns.
- Assess the impact of this regulatory setback on pSivida's royalty revenue projections.
- Review the full text of the press release filed as Exhibit 99.1 for additional details.